For years, early-stage biotech companies have operated with a relatively clear value logic: strong science, a meaningful unmet need, and a compelling clinical profile would translate into a credible commercial opportunity. That foundation, while still essential, is no longer sufficient. As Most Favored Nation (MFN) pricing dynamics introduce greater interconnectedness across global markets, companies face growing uncertainty around long-term asset value and increasing pressure to explain and defend that value under multiple possible futures.
For early-stage biotechs, MFN is a valuation challenge. Investors and potential partners are increasingly evaluating assets through a scenario-based lens, assessing how value may change under different pricing, access, and policy outcomes. This shift is raising expectations around pricing strategy, launch sequencing, evidence generation, partnering approaches, and the ability to demonstrate resilience across different market and policy environments.
In this whitepaper, we explore how MFN is changing value creation for early-stage biotech companies and changing the questions investors are asking. We examine the implications for both US and ex-US biotechs, discuss how companies can integrate pricing and access considerations earlier in development, and outline practical approaches for building value resilience in a more interconnected global pricing landscape.
